14 May 2021 - The MSAC Secretariat has published a list of the applications scheduled to be considered at the next Evaluation Sub-Committee in June.
The Sub-Committee will consider 11 items including brexucabtagene autoleucel for patients with relapsed or refractory mantle cell lymphoma.